Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Structure-guided design and development of cyclin-dependent kinase 4/6 inhibitors: A review on therapeutic implications
Mohd Yousuf, Manzar Alam, Anas Shamsi, et al.
International Journal of Biological Macromolecules (2022) Vol. 218, pp. 394-408
Closed Access | Times Cited: 25

Showing 25 citing articles:

Recent progress of CDK4/6 inhibitors’ current practice in breast cancer
Xueqing Wang, Shanshan Zhao, Qinghan Xin, et al.
Cancer Gene Therapy (2024) Vol. 31, Iss. 9, pp. 1283-1291
Open Access | Times Cited: 39
Investigating regulated signaling pathways in therapeutic targeting of non-small cell lung carcinoma
Manzar Alam, Gulam Mustafa Hasan, Sayed M. Eldin, et al.
Biomedicine & Pharmacotherapy (2023) Vol. 161, pp. 114452-114452
Open Access | Times Cited: 26
Biochemical features and therapeutic potential of α-Mangostin: Mechanism of action, medicinal values, and health benefits
Manzar Alam, Summya Rashid, Kisa Fatima, et al.
Biomedicine & Pharmacotherapy (2023) Vol. 163, pp. 114710-114710
Open Access | Times Cited: 24
Intelligent delivery system targeting PD-1/PD-L1 pathway for cancer immunotherapy
Ning Liu, Renshuai Zhang, Qiang Shi, et al.
Bioorganic Chemistry (2023) Vol. 136, pp. 106550-106550
Closed Access | Times Cited: 18
Therapeutic Targeting of Regulated Signaling Pathways of Non-Small Cell Lung Carcinoma
Gulam Mustafa Hasan, Md. Imtaiyaz Hassan, Sukhwinder Singh Sohal, et al.
ACS Omega (2023) Vol. 8, Iss. 30, pp. 26685-26698
Open Access | Times Cited: 16
Design, Synthesis, and Biological Evaluation for First GPX4 and CDK Dual Inhibitors
Jiangmin Zhu, Yuxing Cai, Min Kong, et al.
Journal of Medicinal Chemistry (2024) Vol. 67, Iss. 4, pp. 2758-2776
Closed Access | Times Cited: 6
Disproportionality Analysis of Abemaciclib in the FDA Adverse Event Reporting System: A Real-World Post-Marketing Pharmacovigilance Assessment
Yamin Shu, Lei Wang, Yiling Ding, et al.
Drug Safety (2023) Vol. 46, Iss. 9, pp. 881-895
Closed Access | Times Cited: 13
PhosAF: An integrated deep learning architecture for predicting protein phosphorylation sites with AlphaFold2 predicted structures
Ziyuan Yu, Jialin Yu, Hongmei Wang, et al.
Analytical Biochemistry (2024) Vol. 690, pp. 115510-115510
Closed Access | Times Cited: 5
Influence of gut and lung dysbiosis on lung cancer progression and their modulation as promising therapeutic targets: a comprehensive review
Rajan Thapa, A Magar, Jesus Shrestha, et al.
MedComm (2024) Vol. 5, Iss. 12
Open Access | Times Cited: 5
Cyclin-dependent kinase 4 and 6 in cancer: Exploration of CDK4/6 inhibitors as anticancer agents
Nilay Kumar Nandi, Chahat, Rohit Bhatia, et al.
Elsevier eBooks (2024), pp. 115-137
Closed Access | Times Cited: 4
Real-world experience with CDK4/6 inhibitors in hormone receptor-positive metastatic and recurrent breast cancer: findings from an Asian population
Bo-Fang Chen, Yi-Fang Tsai, Ta-Chung Chao, et al.
Clinical and Experimental Medicine (2024) Vol. 24, Iss. 1
Open Access | Times Cited: 4
Integrated virtual screening and MD simulation study to discover potential inhibitors of Lyn-kinase: targeting cancer therapy
Md. Imtaiyaz Hassan, Darakshan Anjum, Taj Mohammad, et al.
Journal of Biomolecular Structure and Dynamics (2022) Vol. 41, Iss. 20, pp. 10558-10568
Closed Access | Times Cited: 18
Therapeutic targeting of microtubule affinity‐regulating kinase 4 in cancer and neurodegenerative diseases
Manzar Alam, Sarfraz Ahmed, Mohammad Abid, et al.
Journal of Cellular Biochemistry (2023) Vol. 124, Iss. 9, pp. 1223-1240
Open Access | Times Cited: 9
A disproportionality analysis of CDK4/6 inhibitors in the FDA adverse event reporting system (FAERS)
Yuan Peng, Yuying Zhou, Xuanyi Zhou, et al.
Expert Opinion on Drug Safety (2024), pp. 1-9
Open Access | Times Cited: 3
A review on regulation of cell cycle by extracellular matrix
Ashar Rais, Afzal Husain, Gulam Mustafa Hasan, et al.
International Journal of Biological Macromolecules (2023) Vol. 232, pp. 123426-123426
Closed Access | Times Cited: 8
Cerebral venous sinus thrombosis in a patient treated with ribociclib for metastatic breast cancer. Case reports and literature review
Baha’ Sharaf, Zeina Othman, Hala Abu Faris, et al.
SAGE Open Medical Case Reports (2024) Vol. 12
Open Access | Times Cited: 2
Spectral, XRD, morphological, DFT, and molecular modeling investigations of newly prepared isatin Schiff base complexes
Bassant S. Moustafa, M. M. Omar, Wesam S. Qayed, et al.
Applied Organometallic Chemistry (2024) Vol. 38, Iss. 8
Closed Access | Times Cited: 2
Hiding in plain sight: Optimizing topoisomerase IIα inhibitors into Hsp90β selective binders
Jaka Dernovšek, Tjaša Goričan, Marius Gedgaudas, et al.
European Journal of Medicinal Chemistry (2024) Vol. 280, pp. 116934-116934
Open Access | Times Cited: 2
Identification of abemaciclib derivatives targeting cyclin-dependent kinase 4 and 6 using molecular dynamics, binding free energy calculation, synthesis, and pharmacological evaluation
Yanting Zhou, Xiandeng Li, Peifang Luo, et al.
Frontiers in Pharmacology (2023) Vol. 14
Open Access | Times Cited: 3
A patent review of small molecule CDK4/6 inhibitors in the treatment of cancer: 2020—present
Xiaoling Huang, Shidi Xu, Lei Duan, et al.
Expert Opinion on Therapeutic Patents (2024) Vol. 34, Iss. 9, pp. 825-842
Closed Access
Potential Target of CDK6 Signaling Pathway for Cancer Treatment
Rajesh Basnet, Obed Boadi Amissah, Buddha Bahadur Basnet, et al.
Current Drug Targets (2024) Vol. 25, Iss. 11, pp. 724-739
Closed Access
Discovering Therapeutic Candidates for Lung Cancer via PDK3 Inhibition – A drug repurposing approach
Zeba Firdos Khan, Aanchal Rathi, Afreen Khan, et al.
Research Square (Research Square) (2024)
Open Access
Consensus Guidelines for the Use of Cyclin-Dependent Kinase (CDK) 4/6 Inhibitors in the Management of Hormone Receptor Positive (HR+ve), Her2−ve Early Breast Cancer (EBC)
Purvish M. Parikh, Amish Vora, Rajan Yadav, et al.
South Asian Journal of Cancer (2024) Vol. 14, Iss. 01, pp. 045-052
Open Access
Exploring PDK3 inhibition in lung cancer through drug repurposing for potential therapeutic interventions
Zeba Firdos Khan, Aanchal Rathi, Afreen Khan, et al.
Scientific Reports (2024) Vol. 14, Iss. 1
Open Access
Sanguinarine promotes apoptosis of hepatocellular carcinoma cells via regulating the miR-497-5p/CDK4 axis.
Quanhua Ding, Weina Zhu, Shenghao Zhu, et al.
PubMed (2022) Vol. 14, Iss. 12, pp. 8539-8551
Closed Access
Page 1

Scroll to top